Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

John J.V. McMurray, Fredrik L. Andersson, Simon Stewart, Klas Svensson, Alain Cohen Solal, Rainer Dietz, Johan Vanhaecke, Dirk J. Van Veldhuisen, Jan Östergren, Christopher B. Granger, Salim Yusuf, Marc A. Pfeffer, Karl Swedberg

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Aims: More treatments are needed to improve clinical outcomes in chronic heart failure (HF). It is, however, important that treatments for a condition as common as HF are affordable. We have carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Methods and results: Patients with NYHA class II-IV HF and LVEF ≤0.40 were randomized to CHARM-Alternative if intolerant of an ACE-inhibitor or to CHARM-Added if taking an ACE-inhibitor. Patients with a LVEF >0.40 were randomized in CHARM-Preserved. Each trial compared the effect of candesartan to placebo on the primary outcome of cardiovascular death or HF hospitalization. Detailed information was prospectively collected on hospital admissions, procedures/operations and drugs. A cost-consequence analysis was performed for France, Germany and the UK for CHARM-Overall and a cost-effectiveness analysis for the low LVEF trials. The cost of candesartan was substantially offset by a reduction in hospital admissions, especially for HF. In the cost-consequence analysis, candesartan was cost-saving in most scenarios for CHARM-Alternative and Added but the marginal annual net cost per patient was upto €372 per year in CHARM-Preserved, in which candesartan did not reduce the primary outcome significantly. In the cost-effectiveness analysis of patients with a LVEF ≤ 0.40, candesartan was cost-saving in some scenarios and in the others the maximum cost per life year gained was €3881. Conclusion: Candesartan improves functional class, reduces the risk of hospital admission, and increases survival in patients with a HF and a LVEF ≤0.40 at an acceptable cost.

Original languageEnglish
Pages (from-to)1447-1458
Number of pages12
JournalEuropean Heart Journal
Volume27
Issue number12
DOIs
Publication statusPublished - 1 Jun 2006
Externally publishedYes

Keywords

  • Angiotensin receptor blocker
  • Cost-effectiveness
  • Health economics
  • Heart failure

Fingerprint Dive into the research topics of 'Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme'. Together they form a unique fingerprint.

  • Cite this

    McMurray, J. J. V., Andersson, F. L., Stewart, S., Svensson, K., Solal, A. C., Dietz, R., Vanhaecke, J., Van Veldhuisen, D. J., Östergren, J., Granger, C. B., Yusuf, S., Pfeffer, M. A., & Swedberg, K. (2006). Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 27(12), 1447-1458. https://doi.org/10.1093/eurheartj/ehl016